ES2909557T3 - Utilización de la pridopidina para el tratamiento del síndrome de Rett - Google Patents
Utilización de la pridopidina para el tratamiento del síndrome de Rett Download PDFInfo
- Publication number
- ES2909557T3 ES2909557T3 ES17851614T ES17851614T ES2909557T3 ES 2909557 T3 ES2909557 T3 ES 2909557T3 ES 17851614 T ES17851614 T ES 17851614T ES 17851614 T ES17851614 T ES 17851614T ES 2909557 T3 ES2909557 T3 ES 2909557T3
- Authority
- ES
- Spain
- Prior art keywords
- pridopidine
- subject
- composition
- administered
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395854P | 2016-09-16 | 2016-09-16 | |
| PCT/US2017/051803 WO2018053280A1 (en) | 2016-09-16 | 2017-09-15 | Use of pridopidine for treating rett syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2909557T3 true ES2909557T3 (es) | 2022-05-09 |
Family
ID=61619744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17851614T Active ES2909557T3 (es) | 2016-09-16 | 2017-09-15 | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| ES22150695T Active ES2986807T3 (es) | 2016-09-16 | 2017-09-15 | Pridopidina para su uso en el tratamiento del síndrome de Rett |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22150695T Active ES2986807T3 (es) | 2016-09-16 | 2017-09-15 | Pridopidina para su uso en el tratamiento del síndrome de Rett |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP4005570B1 (enExample) |
| JP (1) | JP6977029B2 (enExample) |
| CN (1) | CN109982686A (enExample) |
| AU (1) | AU2017326013B2 (enExample) |
| BR (1) | BR112019005040A2 (enExample) |
| CA (1) | CA3036984C (enExample) |
| DK (2) | DK4005570T3 (enExample) |
| ES (2) | ES2909557T3 (enExample) |
| HU (1) | HUE058314T2 (enExample) |
| IL (1) | IL265342B2 (enExample) |
| MX (1) | MX388845B (enExample) |
| PL (2) | PL3512506T3 (enExample) |
| WO (1) | WO2018053280A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP2022524927A (ja) | 2019-02-02 | 2022-05-11 | ステモニックス インコーポレイティド | 創薬のためのヒトスフェロイドの使用方法 |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| CA2937243C (en) * | 2014-01-22 | 2023-07-18 | Teva Pharmaceuticals International Gmbh | Modified release formulations of pridopidine |
| EP3854785A1 (en) * | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
-
2017
- 2017-09-15 ES ES17851614T patent/ES2909557T3/es active Active
- 2017-09-15 BR BR112019005040A patent/BR112019005040A2/pt not_active Application Discontinuation
- 2017-09-15 EP EP22150695.9A patent/EP4005570B1/en active Active
- 2017-09-15 WO PCT/US2017/051803 patent/WO2018053280A1/en not_active Ceased
- 2017-09-15 CN CN201780071045.XA patent/CN109982686A/zh active Pending
- 2017-09-15 DK DK22150695.9T patent/DK4005570T3/da active
- 2017-09-15 HU HUE17851614A patent/HUE058314T2/hu unknown
- 2017-09-15 JP JP2019514217A patent/JP6977029B2/ja active Active
- 2017-09-15 DK DK17851614.2T patent/DK3512506T3/da active
- 2017-09-15 MX MX2019003069A patent/MX388845B/es unknown
- 2017-09-15 PL PL17851614T patent/PL3512506T3/pl unknown
- 2017-09-15 PL PL22150695.9T patent/PL4005570T3/pl unknown
- 2017-09-15 AU AU2017326013A patent/AU2017326013B2/en active Active
- 2017-09-15 CA CA3036984A patent/CA3036984C/en active Active
- 2017-09-15 EP EP17851614.2A patent/EP3512506B1/en active Active
- 2017-09-15 ES ES22150695T patent/ES2986807T3/es active Active
-
2019
- 2019-03-13 IL IL265342A patent/IL265342B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019003069A (es) | 2019-09-02 |
| PL3512506T3 (pl) | 2022-05-30 |
| EP4005570A1 (en) | 2022-06-01 |
| DK3512506T3 (da) | 2022-04-19 |
| CN109982686A (zh) | 2019-07-05 |
| MX388845B (es) | 2025-03-20 |
| BR112019005040A2 (pt) | 2019-07-16 |
| AU2017326013B2 (en) | 2020-12-24 |
| EP3512506A1 (en) | 2019-07-24 |
| JP6977029B2 (ja) | 2021-12-08 |
| DK4005570T3 (da) | 2024-08-19 |
| EP4005570B1 (en) | 2024-05-15 |
| EP3512506B1 (en) | 2022-01-26 |
| HUE058314T2 (hu) | 2022-07-28 |
| AU2017326013A1 (en) | 2019-04-11 |
| ES2986807T3 (es) | 2024-11-12 |
| CA3036984A1 (en) | 2018-03-22 |
| IL265342A (en) | 2019-05-30 |
| EP3512506A4 (en) | 2020-05-27 |
| WO2018053280A1 (en) | 2018-03-22 |
| PL4005570T3 (pl) | 2024-09-23 |
| JP2019532926A (ja) | 2019-11-14 |
| CA3036984C (en) | 2023-07-18 |
| IL265342B2 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2986807T3 (es) | Pridopidina para su uso en el tratamiento del síndrome de Rett | |
| Quinn et al. | PINK1/PARKIN signalling in neurodegeneration and neuroinflammation | |
| CN102065897B (zh) | 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用 | |
| JP5875191B2 (ja) | Ｃｍｔ及び関連障害を処置するための新たな組成物 | |
| US20200276136A1 (en) | Method of treating selected patient population experiencing dravet syndrome | |
| US20190247333A1 (en) | Method of reduction in convulsive seizure frequency | |
| KR20160037169A (ko) | 레트 증후군 및 그를 위한 치료 | |
| AU2024266870A1 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| US10113171B2 (en) | Methods for improving cognitive function via modulation of quinone reductase 2 | |
| US20210393591A1 (en) | Treatments for charcot-marie-tooth disease | |
| US20240398778A1 (en) | Use of pridopidine for treating rett syndrome | |
| CN108601772A (zh) | 用于治疗tdp-43蛋白质病的他克莫司 | |
| AU2021383325B2 (en) | Use of pridopidine and analogs for treating rett syndrome | |
| HK40009961B (en) | Use of pridopidine for treating rett syndrome | |
| RU2799049C2 (ru) | Способы лечения изменений поведения | |
| de Brito | Pharmacological Modulation of Mutant Ataxin-3 Translation and It Potential Therapeutic Effect in Machado Joseph Disease | |
| TW201929850A (zh) | 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途 | |
| GB2558788A (en) | New therapeutic uses |